US sues Regeneron over ‘hundreds of millions’ in allegedly inflated Medicare reimbursements for Eylea
Regeneron Pharmaceuticals has been accused of manipulating Medicare reimbursement for its eye drug Eylea. If found liable, the company could end up paying three times the amount that Medicare lost — which was estimated at “hundreds of millions of dollars” — plus potential penalties, the government said.
On April 10, the US attorney’s office in the District of Massachusetts said it filed a complaint against Regeneron under the False Claims Act at a federal court in Boston.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
